The ROC analysis confirmed that the sensitivity and specificity of TRIB2/MAP3K1 expression were statistically significant, indicating that TRIB2/MAP3K1 expression should be investigated for evaluating the prognosis and therapeutic efficacy in patients with glioma. The gene discussed is TRIB2; the disease is glioma.